New York: Pfizer Inc research chief Mikael Dolsten said the company`s experimental treatment for Alzheimer`s disease is the drug industry`s "best chance" to delay progression of the memory-robbing illness.Dolsten, speaking at the BIO CEO and investor conference in New York, stopped short of predicting whether the drug being developed with Johnson & Johnson would meet that goal."This is so far the best chance the industry has for disease modification in Alzheimer`s," he said. Dolsten said Pfizer`s drug, bapineuzumab, had far more complete and compelling data from already finished mid-stage clinical trials than Eli Lilly and Co`s solanezumab.
Rahul Gandhi falls asleep in Parliament
Firing inside UP`s Faizabad court, two dead
Amit Shah: From backroom boy to BJP`s chief
Marrow Donor Registry of India launches Gujarat chapter